一年一度的全球盛会——第27届美国基因与细胞治疗学会年会 (ASGCT 2024) 将于当地时间2024年5月7日~11日在美国马里兰州巴尔的摩盛大召开。将携多款创新技术和产品重磅参展,欢迎您莅临现场参观交流,精彩活动,敬请期待。
话题1:The future of viral vector manufacturing: Is it time for cell lines to take center stage?
时间:5月9日周四中午12:15–1:15pm,Room 327-329
演讲者:Clive Glover (),Sybil Danby ()
Barry Byrne (Powell Gene Therapy Center at the University of Florida)
Kimberly Benton (Dark Horse Consulting)
Markus Haindl (Roche Diagnostics)
Nicole Paulk (Siren Biotechnology)
话题2:Ex vivo engineering of T cells and hematopoietic stem cells using RNA-lipid nanoparticles for cell and gene therapies
时间:5月9日周四下午4:45-5:15pm, Room 337-338
演讲者:Dr. Angela Zhang, Product Management Leader ()
话题3:Generation of a stable high-titer production cell line for therapeutic AAV vectors
时间:5月10日周五下午5:15-5:30pm, Ballroom 3 (Abstract #295)
演讲者:Stefan Seeber (Roche)
话题4:Comparative Analysis of Sterile Grade Filters in Adeno-Associated Virus (AAV) Manufacturing: Accelerating First-in-Human AAV Therapeutic Production with Quality by Design Principles
时间:5月8日周三下午3:00-3:15pm | Ballroom 3 (Abstract #66)
演讲者:Angela N. Johnson, PHD, MSE, RAC ()
话题5:Systematic analysis of primary field data from biologics therapy regulatory non-approvals: Why aren’t we talking about FDA rejections?
时间:5月8日周三下午5:10-5:27pm | Rooms 314-317 (Abstract #128)
演讲者:Limin Wang, Lead Regulatory Strategist ()
*Transient即将上市,若您对现场展示的产品或解决方案感兴趣,可与技术专家现场交流。
Abstract编号#531:Membrane Chromatography for Preparation of AAV at the Manufacturing Scale
[Wednesday Posters: AAV Vectors -Product Development Manufacturing and Approval Considerations]
Abstract编号#559:ELEVECTA Transient Cell Line: Enabling rAAV Production with Low-Level hcDNA Encapsidation
[Wednesday Posters: AAV Vectors - Product Development Manufacturing and Approval Considerations]
Abstract编号#1053:Evaluation of Cell Growth and AAV Production in a Fixed-Bed Bioreactor to Streamline Process Development
[Thursday Posters: AAV Vectors - Product Development Manufacturing and Approval Considerations]
Abstract编号#1159:Comparative Interrater Analysis of Regulatory Challenges in Recently Approves Gene Therapies for Sickle Cell Disease: Towards a Semi-Quantitative Method for Assessing Gene Therapy Regulatory Development Complexity
[Thursday Posters: Genetic Disorders of the Blood and Immune System]
Abstract编号#1190:Optimization of Multiplex CRISPR-Cas9 Editing of Human Primary T Cells Using Lipid Nanoparticles (LNP’s) and Subsequent Off-Target Evaluation
[Thursday Posters: Gene Disruption and Excision]
Abstract编号#1245:Efficient Gene Editing in CD34+ Hematopoietic Stem and Progenitor Cells Using Non-Viral Lipid Nanoparticles
[Thursday Posters: Other Nonviral Delivery]
Abstract编号#1258:Strategies for Producing Clinical and Commercial RNA-LNP Drug Products
[Thursday Posters: Other Nonviral Delivery]
Abstract编号#1720:Effect of LNP Components on mRNA Mediated Protein Expression of Lipid Nanoparticles in Different Organs
[Friday Posters: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates]
Abstract编号#1748:Gene Editing in Liver Towards the Treatment of Life-Threatening Cardiovascular Diseases: POC for Efficient In-Vivo Genome Editing/Base Editing Using Lipid Nanoparticle Library
[Friday Posters: Other Nonviral Delivery]
Abstract编号#1818:Development and Evaluation of Immuno-Cell Growth Medium (Akron ICGM?): A Novel Xeno-Free Cell Expansion Medium Demonstrated to Support Superior Cell Activation, Viability, Transduction and Expansion
[Friday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies]
Abstract编号#1845:Navigating Pitfalls in the Adenovirus Development: From Drug Discovery to Clinics and Beyond
[Friday Posters: Vector Product Engineering, Development, and Manufacturing]
基因药物如基于病毒载体的基因疗法和RNA脂质纳米颗粒 (RNA-LNP) 等正在开拓新的领域。尽管新疗法已经取得了一定的进展,但这些技术的发展潜力几乎是无限的。当您对科学进行创新时,也从未止步,始终致力于让您比以往更快、更高效、更节省成本的发现、开发并推进商业化进程。无论您使用何种基因递送方式,都会为您提供合适的解决方案。
声明:本文为作者原创首发,严禁私自转发或抄袭,如需转载请联系并注明转载来源,否则将追究法律责任
参与评论
登录后参与评论